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Therapeutic eﬀects of GCSB-5 on osteoarthritis were measured by the amount of glycosaminoglycan in rabbit articular cartilage
explants in vitro, in experimental osteoarthritis induced by intra-articular injection of monoiodoacetate in rats in vivo.G C S B - 5
was orally administered for 28 days. In vitro, GCSB-5 inhibited proteoglycan degradation. GCSB-5 signiﬁcantly suppressed the
histological changes in monoiodoacetate-induced osteoarthritis. Matrix metalloproteinase (MMP) activity, as well as, the levels of
serum tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase protein, and mRNA expressions were attenuated
by GCSB-5, whereas the level of interleukin-10 was potentiated. By GCSB-5, the level of nuclear factor-κB p65 protein expression
was signiﬁcantly attenuated but, on the other hand, the level of inhibitor of κB-α protein expression was increased. These results
indicate that GCSB-5 is a potential therapeutic agent for the protection of articular cartilage against progression of osteoarthritis
through inhibition of MMPs activity, inﬂammatory mediators, and NF-κB activation.
1.Introduction
Osteoarthritis (OA) is a degenerative joint disease charac-
terized by joint pain and a progressive loss of articular carti-
lage. It has been suggested that biochemical alterations occur
within the articular cartilage resulted in imbalance between
synthetic and degradative pathways [1]. A key step in the
pathophysiology of OA is breakdown of extracellular matrix
of articular cartilage by tissue proteinases, enzymes whose
expression is upregulated by inﬂammatory stimuli, such as
primary inﬂammatory cytokines [2]. Nonsteroidal anti-in-
ﬂammatorydrugs(NSAIDs)areeﬀectiveinthemanagement
of OA inﬂammation. However, the adverse events secondary
to NSAIDs was focused on upper gastrointestinal tolerability
[3]. In recent years, gene therapy targeted at cytokines of-
fers new hope to OA treatment, and the current focus is
on the use of biological agents that block the activity of in-
ﬂammatory cytokines [4]. Since there are many proinﬂam-
matory cytokines, oxidants and other factors exerting action
in initiation and development of OA, it is hard to obtain
complete therapeutic eﬀects by blocking the activity of
one or two cytokines. Developing therapeutics from herbal
sources may reduce the risk of toxicity or adverse eﬀects
when the drug is clinically used [5] and may exert strong,
multifunctional anti-inﬂammatory eﬀect like many natural
products do. Therefore, eﬀorts are being made to elucidate
the role of natural products for the treatment of OA.
GCSB-5 is a puriﬁed extract from a mixture of 6 oriental
herbs which are the ingredients of Chung-Pa-Juhn used in
Jaseng Hospital (Seoul, Korea) and that have been used in
traditionalmedicinetotreatinﬂammatorydiseasesandbone
disorders. Ledebouriellae Radix is reported to have anti-
inﬂammatory eﬀects on Freund’s adjuvant-induced arthritis
in rats [6]. Cimifugin, a major active component of Lede-
bouriellae Radix, exhibits inhibitory eﬀects on the synthesis
of NO induced by LPS in macrophage cell line RAW 264.7
[7]. Achyranthis Radix shows anti-inﬂammatory property
and inhibits free radicals, such as ONOO−, HOCl, and OH
radical [8]. 20-Hydroxyecdysone, which is a major active
compound of Achyranthis Radix, has beneﬁcial eﬀects on2 Evidence-Based Complementary and Alternative Medicine
j o i n ta n db o n ei no v a r i e c t o m i z e dr a t s[ 9]. Acanthopanacis
Cortex is known to show antiarthritic activity [10], and
Cibotii Rhizoma is known for its analgesic property [11]
along with osteoclast formation inhibition [12]. Glycine
Semen is eﬀective in reducing swelling [13] and genistin,
an active compound from Glycine Semen, shows beneﬁcial
eﬀect on bone loss [14]. Eucommiae Cortex exhibits strong
analgesic eﬀect [15] and geniposide from its extract shows
anti-inﬂammatory eﬀect on rheumatoid arthritis rats [16]
and enhances the osteoblast-like cell proliferation and inhib-
ited osteoclast [17]. We reported strong antinociceptive and
anti-inﬂammatory properties of GCSB-5 [11, 13]. Recently,
GCSB-5 reduces the development of acute and chronic in-
ﬂammation, and its anti-inﬂammatory property is likely due
to inhibition of inducible nitric oxide synthase (iNOS) and
cyclooxygenase (COX)-2 expression via downregulation of
the Akt signal pathway and inhibition of nuclear factor-κB
(NF-κB) activation [18]. In phase III clinical study, GCSB-5
was shown to exert therapeutic eﬀects and acted to reduce
OA severity and improved functional recovery without
apparent hepatic or renal toxicity (unpublished data).
In this study, we examined the chondroprotective and
anti-inﬂammatory eﬀects of GCSB-5 on monoiodoacetate
(MIA)-induced OA animal model, both in vitro and in vivo.
2.MaterialsandMethods
2.1. Preparation and Composition of GCSB-5. GCSB-5 was
prepared by the Hanpoong Pharmaceutical Co., Ltd., Jeonju,
Republic of Korea. The mixture of six crude drugs (Lede-
bouriellae Radix (4.444g), Achyranthis Radix (4.444g),
Acanthopanacis Cortex (4.444g), Cibotii Rhizoma (2.778g),
Glycine Semen (2.778g), and Eucommiae Cortex (1.389g))
was powdered and boiled for 3h in distilled water (1L).
The resulting extract was subjected to ultraﬁltration, and
the components with molecular weight over 10,000 were
excluded. The ﬁltrate was lyophilized as powder and kept
at 4◦C until use. GCSB-5 was administered orally at a dose
of 300 and 600mg/kg in saline (1kg/10mL), and the same
volume of saline was used as a vehicle control group. The
validation of GSCB-5 was performed by high-performance
liquid chromatography analysis of each ingredient ex-
tract using six indicator biological components: cimifu-
gin for Ledebouriellae Radix, 20-hydroxyecdysone (0.311-
0.312mg/g) for Achyranthis Radix, acanthoside D (0.577-
0.578mg/g) for Acanthopanacis Cortex, onitin-4-O-β-D-
glucopyranoside for Cibotii Rhizoma, genistin (0.0426-
0.0427mg/g) for Glycine Semen, and geniposide (0.431-
0.432mg/g) for Eucommiae Cortex. GCSB-5 was further
standardized for quality control according to the regulations
imposed by Korea Food and Drug Administration (KFDA).
2.2.Chemicals.Dulbecco’smodiﬁedEagle’smedium(DMEM),
penicillin/streptomycin (10,000U/mL, 10,000μg/mL, resp.),
and fetal bovine serum (FBS) were obtained from Gibco
BRL, Life Technologies (Grand Island, NY, USA). All the
other materials required for culturing of tissue were pur-
chased from Sigma Chemical Company (St. Louis, MO,
USA).
2.3. Animals. Male Sprague-Dawley rats (200–220g) and
male New Zealand white rabbits (2.0–2.2kg) were obtained
from Dae Han Biolink Ltd. (Eumseong, Korea) and housed
in solid bottom cages with pellet food and water available ad
libitum. All animal procedures were approved by the Sung-
kyunkwan University Animal Care Committee and were per-
formed in accordance with the guidelines of the National
Institutes of Health.
2.4. Cartilage Glycosaminoglycan Assay. Rabbit knee articu-
lar cartilage explants were obtained according to the method
described by Sandy et al. [19]. Brieﬂy, 200–220mg articu-
lar surfaces per joint were dissected and submerged into
complete medium of DMEM supplemented with heat-inac-
tivated 5% FBS, penicillin (100U/mL), and streptomycin
(100μg/mL). After stabilization in incubator, the medium
was replaced with basal medium made of DMEM supple-
mented with heat-inactivated 1% FBS, 10mM HEPES, peni-
cillin (100 U/mL), and streptomycin (100μg/mL). Cartilage
pieces (50–60mg; 2 × 3 × 0.35mm/piece) were placed in
24-well cell culture plates and treated with GCSB-5 at 1 ×
10
−3,1× 10
−2,a n d1× 10
−1 mg/mL or 30μM diclofenac
(Sigma-Aldrich,St.Louis,MO,USA).After1hofGCSB-5or
diclofenac pretreatment, 5ng/mL of rhIL-1α (R&D Systems,
Minneapolis, MN, USA) was added and further incubated
at 37◦C in a humidiﬁed 5% CO2/95% air incubator. The
amountofglycosaminoglycan(GAG)inthemediumwasde-
termined by the 1,9-dimethyl-methylene blue method using
the Blyscan Sulfated GAG Assay kit (Biocolor Ltd., County
Antrim, UK) according to the manufacturer’s instructions.
2.5. MIA-Induced OA. Rats were anesthetized with diethyl
ether and given a single intra-articular injection of 3mg MIA
(Sigma-Aldrich, St. Louis, MO, USA) through the infrap-
atellar ligament of the left knee [20]. MIA was dissolved in
physiologicalsalineandadministeredina50μLv olume.Rats
were treated with saline, with 300 or 600mg/kg of GCSB-5
or with 5mg/kg of diclofenac by oral administration once
daily, for 2, 7, and 28 days since MIA injection. These GCSB-
5 doses and MIA injection volume were selected based on
previous evaluations [21].
2.6. Gross Observation. After MIA injection, all experimental
rats were weighed and carefully inspected every 2 days to as-
sess knee joint swelling and gait disturbances under natural
conditions in the cages, where they moved freely. Swelling
and limping were classiﬁed as no change, mild, and severe on
thebasisofseverity[22],andinspectionwasconductedbyan
inspector blinded to treatment details throughout the study.
2.7. Roentgenographic Examination and Histopathological
Analysis. Seven and 28 days following MIA injection, rats
were checked with roentgenography to assess chronic mor-
phological changes of knee articular bones for narrowing,
loss of joint region, cartilage erosion, and osteophyte forma-
tion [23]. For histological analysis, knee joints were removed
and ﬁxed in 10% neutral buﬀered formalin, decalciﬁed with
10%formicacid,andembeddedinparaﬃn.FivemicrometerEvidence-Based Complementary and Alternative Medicine 3
Table 1: RT-PCR primers used in study.
Gene Accession number Primer sequences (5  → 3 ) Product length (bp)
TNF-α X66539 Sense: GTA GCC CAC GTC GTA GCA AA 346
Antisense: CCC TTC TCC AGC TGG AAG AC
iNOS D44591 Sense: TTC TTT GCT TCT GTG CTT AAT GCG 1061
Antisense: GTT GTT GCT GAA CTT CCA ATC GT
COX-2 U03389 Sense: CTG CAT GTG GCT GAT GTC ATC 1061
Antisense: AGG ACC CGT CAT CTC CAG GGT AAT C
IL-1β M98820 Sense: TGA TGT TCC CAT TAG ACA GC 378
Antisense: GAG GTG CTG ATG TAC CAG TT
IL-10 X60675 Sense: CAG TCA GCC AGA CCC ACA T 322
Antisense: GCT CCA CTG CCT TGC TTT
β-Actin V01217 Sense: TTG TAA CCA ACT GGG ACG ATA TGG 764
Antisense: GAT CTT GAT CTT CAT GGT GCT AG
(5μm) sections were stained with hematoxylin and eosin
(H and E) or safranin-O fast green (SOFG) and observed.
Histopathologicalchangesineachanimalwerequantitatively
expressed by three grades for each ﬁnding [24]. Grading was
done under the authority of Medplan Pathology Laborato-
ries, Seoul, Korea.
2.8.GelatinaseAssay. RatarticularcartilagesamplesofMIA-
induced OA were harvested 7 and 28 days after MIA injec-
tion. Gelatinase activities were measured by the gelatin zy-
mographymethoddescribedbyDumondetal.[25].Proteins
were extracted from pulverized cartilage tissues and elec-
trophoresed on 10% zymogram precast gels. The cleared gels
were captured, and the area of each band was quantiﬁed with
densitometric scanning analysis program (Science Lab 98
Image Gauge, version 3.12, Fuji Photo Film Co. Ltd., Tokyo,
Japan).
2.9. Serum Cytokine Levels. Commercial tumor necrosis
factor (TNF)-α, interleukin (IL)-1β, and IL-10 enzyme-
linked immunosorbent assay (ELISA) kits (BD Biosciences
Co., CA, USA) were used for quantiﬁcation of the serum
levels of TNF-α,I L - 1 β, and IL-10, respectively.
2.10. Western Blot Immunoassay. 15μg of whole protein was
used for determination of the content of COX-2 and iNOS.
20μg of nuclear protein was used for determination of the
content of the NF-κB/p65 subunit. 20μg of the cytosolic
protein was used for determination of the content of the
inhibitorofκB(IκB)-α.ImageQuantTMTLsoftware(Amer-
sham Biosciences/GE Healthcare, Piscataway, NJ, USA) was
used for densitometric evaluation of visualized immunore-
active bands. The following primary antibodies were used:
COX-2 (Abcam, Cambridge, UK; 1:1000), iNOS (Trans-
duction Lab., CA, USA; 1:1000), phosphoryl NF-κB/p65
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:1000),
and IκB-α (Santa Cruz Biotechnology; 1:5000) were used,
and the signals were normalized to that of β-actin (Sigma
Chemical Co.; 1:1000) or lamin B1 (Abcam; 1:2500).
2.11. Total RNA Extraction and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR). Articular cartilage
samples collected 2 and 28 days after MIA injection were
pulverized in TRI Reagent (Molecular Research Center Inc.,
Cincinnati, OH, USA) for RNA extraction. Equal amounts
of RNA from articular cartilages were subjected to reverse
transcriptionusingiNtRONRNAPCRkit(iNtRONBiotech-
nology Co., Seongnam, Korea) to generate cDNA for RT-
PCR analysis. RT-PCR analysis was performed with the
GeneAmp PCR system 2700 (Applied Biosystems Co., Foster
City, CA, USA). The primers used in the RT-PCR are listed
inTable 1.AllPCRreactionsincludedaninitialdenaturation
stepat94◦Cfor5minandaﬁnalextensionat72◦Cfor7min.
The PCR ampliﬁcation cycling conditions were as follows:
32 cycles of 94◦C (30s), 58◦C (30s), and 72◦C (30s) for
TNF-α; 32 cycles of 94◦C (45s), 65◦C (45s), and 72◦C
(60s) for iNOS; 40 cycles of 94◦C (45s), 65◦C( 4 5 s ) ,a n d
73◦C (60s) for COX-2; 36 cycles of 94◦C (30s), 60◦C
(30s), and 72◦C (45s) for IL-1β; 40 cycles of 94◦C (30s),
66◦C (45s), and 72◦C (45s) for IL-10; 30 cycles of 94◦C
(30s), 56◦C (30s), and 72◦C (60s) for β-actin.A f t e rR T -
PCR, 10μL samples of the ampliﬁed products were resolved
by electrophoresis on 1.5% agarose gels and stained with
ethidium bromide. The intensity of each PCR product was
evaluated semiquantitatively using a digital camera (DC120;
Eastman Kodak, Rochester, NY, USA) and a densitometric
scanning analysis program (ID Main; Advanced American
Biotechnology, Fullerton, CA, USA).
2.12. Statistics. All results are presented as mean ± S.E.M.
The overall signiﬁcance of the experimental results was
examined by one-way analysis of variance and the two-tail
Dunnet’s t-test. Diﬀerences between groups were considered
signiﬁcant at P<0.05 with the appropriate Bonferroni
correction for multiple comparisons.
3. Results
3.1. Cartilage Glycosaminoglycan Release. In the control
group, the level of GAG in the culture medium remained4 Evidence-Based Complementary and Alternative Medicine
Table 2: Quantitative summary of gross observations in MIA-induced osteoarthritic rats treated with GCSB-5.
Control
MIA
Vehicle GCSB-5 (mg/kg) Diclofenac
300 600 5mg/kg
Swelling
No change 0 10/10 0/10 1/10 1/10 0/10
Mild 1 0/10 3/10 8/10 6/10 8/10
Severe 2 0/10 7/10 1/10 3/10 2/10
Average score 0.0 ±0.01 .7 ±0.2a 1.0 ±0.2a,b 1.2 ±0.2a 1.2 ±0.1a
Limping
No change 0 10/10 0/10 6/10 5/10 5/10
Mild 1 0/10 7/10 4/10 5/10 5/10
Severe 2 0/10 3/10 0/10 0/10 0/10
Average score 0.0 ±0.01 .3 ±0.2a 0.4 ± 0.2c 0.5 ±0.2c 0.5 ± 0.2c
GCSB-5 or diclofenac was treated daily for 14 days after 2 weeks of OA induction by intra-articular injection of MIA.
aDenotes signiﬁcant diﬀerences (P<0.01) versus the control group.
b,cDenote signiﬁcant diﬀerences (P<0.05, P<0.01) versus the vehicle-treated MIA group.
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Figure 1: GAG release in rabbit articular cartilage explant cultures
at 24, 48, and 72h. Rabbit articular cartilage explants were
stimulated with rhIL-1α (5ng/mL). The amount of GAG release
stimulated by rhIL-1α (◦) increased approximately 3.6 times
compared to control (•)a t7 2 h .G C S B - 5( 1 .0 × 10
−3 ()a n d
1.0 × 10
−2 () mg/mL) and diclofenac (30μM( )) eﬃciently
inhibitedtheGAGrelease. However, ahighconcentration ofGCSB-
5(1.0×10
−1 ()mg/mL)slightlyinhibitedit.Eachvaluerepresents
the mean ± S.E.M. from 6 articular cartilage explants cultures per
group. ∗∗Signiﬁcantly diﬀerent (P<0.01) from control. + and
++Signiﬁcantly diﬀerent (P<0.05, P<0.01) from rhIL-1α.
constant at approximately 1.5μg/mg cartilage throughout
the experiment. In the rhIL-1α-treated group, on the other
hand, the level of GAG in the culture medium dramatically
increased to approximately 4 times the control values.
GCSB-51×10
−3 and 1×10
−2 mg/mL treatments attenuated
the elevation in GAG release at 72h (Figure 1).
3.2. Gross Observation. In the MIA-injected groups, swelling
and limping were ﬁrst observed 7 days after MIA injection.
They subsided transiently and then reappeared at 14 days.
These symptoms gradually aggravated at 21 days (data not
shown) and were the most severe at 28 days. Twenty-
eight days after MIA injection, swelling and limping were
attenuated by both 300 and 600mg/kg GCSB-5 treatment
(Table 2).
3.3. Roentgenographic and Histopathological Analysis. Seven
days after MIA injection, rats underwent the ﬁrst roentgeno-
graphic examination. Their roentgenographic examinations
revealed degenerative changes, such as irregularity or osteo-
phytes on the surface of the cartilage and subchondral bone
(data not shown). At 28 days, rats underwent the second
roentgenographic examination (Figures 2(a)–2(d)). Mor-
phological changes were more signiﬁcant, showing rough
edges of cartilage and the tendency of patellar displace-
ment. These changes were attenuated by GCSB-5 600mg/kg
treatment. Twenty-eight days after MIA injection, H and E
staining revealed irregular surface accompanied by ulcera-
tion, ﬁbrillation, and loss of cartilage tissue (Figures 2(e)–
2(h)). However, these cartilage damages were attenuated by
GCSB-5 600mg/kg treatment. SOFG staining also revealed
clearly diﬀused PG depletion in joint cartilage tissues of
MIA-injected rats (Figures 2(i)–2(l)). This loss of PG was
attenuated by GCSB-5 600mg/kg treatment. Summation of
all histopathologic ﬁnding scores in vehicle-treated MIA
group and in 300 and 600mg/kg GCSB-5-treated MIA
groups were 24.5±1.3, 16.1±1.4, and 12.5±1.1, respectively
(Table 3).
3.4. Gelatinase Assay. Seven days after MIA injection, the
activities of matrix metalloproteinase (MMP)-2 and -9 in-
creased to 2.7 and 2.4 times that in the control group,
respectively. Similarly, 28 days after MIA injection, the
activities of MMP-2 and -9 increased to 2.3- and 2.8-fold
higher than the control level, respectively. On day 7, GCSB-5
and diclofenac treatment showed no signiﬁcant modulation
on MMP activities (data not shown). However, on day 28,
GCSB-5 300mg/kg treatment exhibited signiﬁcant MMP-2Evidence-Based Complementary and Alternative Medicine 5
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picture
H and E
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SOFG
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Control MIA MIA + GCSB-5 MIA + diclofenac
Figure 2: Roentgenography and histopathological features of osteoarthritic lesion in the knee joint of rats 28 days after intra-articular
injection of MIA (H and E staining, ×100; SOFG staining, ×100). Control (a) represents intact normal joint feature. Vehicle-treated MIA
(b) shows a severely damaged joint with rough edges around the tibia and femur, indicative of bone lysis, swelling, and tendency of patellar
displacement. However, these damages were reduced signiﬁcantly by treatment with 600mg/kg GCSB-5 (c) and 5mg/kg diclofenac (d).
SOGF-stained control (e) represents normal cartilage PG staining, whereas vehicle-treated MIA (f) represents severely damaged cartilage
showing marked ﬁbrillation and the depletion of SOFG staining with separation of cartilage from subchondral bone. 600mg/kg GCSB-5 (g)
and 5mg/kg diclofenac (h) treatments signiﬁcantly reduced cartilage damage. H and E stained control (i) represents the normal status of
joint cartilage, whereas vehicle-treated MIA (j) represents severely damaged cartilage showing widespread cell necrosis and inﬂammation.
However, treatment with 600mg/kg GCSB-5 (k) and 5mg/kg diclofenac (l) treatments signiﬁcantly reduced joint cartilage damage.
and -9 activities attenuation (79.6%, P<0.01 and 81.2%,
P<0.01, resp.), while GCSB-5 600mg/kg treatment did not
aﬀect the MMP-2 and -9 activities (91.0% and 91.6%, resp.)
(Figure 3).
3.5.InﬂammatoryMediators. The serumlevelsofTNF-α,IL -
1β, and IL-10 were 30.0 ± 4.5pg/mL,29.1 ± 3.7pg/mL,and
27.8 ± 0.6pg/mL in the control. 2 days after MIA injection,
theserumlevelsofTNF-α,IL-1β,andIL-10increasedto2.8-,
3.4- and 2.2-fold higher than the control level, respectively.
Increase in TNF-α level was signiﬁcantly suppressed by
treatment with GCSB-5, while increase in IL-10 level was
signiﬁcantly potentiated by GCSB-5. However, GCSB-5 did
not aﬀect the serum level of IL-1β (Table 4) .T h el e v e l so f
COX-2 and iNOS protein expression increased 3.3 and 12
times in the vehicle-treated MIA groups, compared to those
in the control group 2 days after MIA injection, respectively
(Figure 5). Increase in COX-2 and iNOS protein expression
was signiﬁcantly suppressed by treatment with GCSB-5.
T h el e v e l so fTNF-α, IL-1β, IL-10, COX-2, and iNOS
mRNA expression increased 5.3, 2.1, 1.3, 7.8 and 8.8 times
in the vehicle-treated MIA groups, compared to those in
the control group 2 days after MIA injection, respectively
(Figures 4 and 6). Increase in TNF-α, COX-2, and iNOS
mRNA expression was signiﬁcantly suppressed by treatment
withGCSB-5.However,GCSB-5didnotaﬀectthelevelofIL-
1β mRNA expression. Interestingly, increase of IL-10 mRNA
expression was signiﬁcantly potentiated by GCSB-5. At 7 and
28 days, there were no signiﬁcant diﬀerences in the level of
inﬂammatorymediatorsmRNAexpressionamonganyofthe
experimental groups (data not shown).
3.6. Nuclear NF-κBa n dC y t o s o l i cI κB-α Immunoblot Assay.
The nuclear localization of NF-κB was measured by the pro-
teinlevelofNF-κBp65subunitinthenucleus.CytosolicIκB-
α was also examined from cytosol fraction as an endogenous
NF-κB inhibitor. The level of nuclear NF-κB p65 protein
expression increased 2.5 times, whereas the level of cytosolic6 Evidence-Based Complementary and Alternative Medicine
Table 3: Summary of microscopic ﬁndings.
MIA
Vehicle GCSB-5 (mg/kg) Diclofenac
300 600 5mg/kg
Structural changes in the joint
Surface irregularities + 0/4 2/4 1/4 2/4
++ 0/4 1/4 2/4 2/4
+++ 4/4 1/4 1/4 0/4
Average pathology score 3 1.8 2 1.5
Ulceration + 0/4 1/4 3/4 1/4
++ 1/4 1/4 1/4 2/4
+++ 3/4 2/4 0/4 1/4
Average pathology score 2.8 2.3 1.3 2
Fibrillation of cartilage surface + 0/4 1/4 2/4 3/4
++ 3/4 3/4 1/4 1/4
+++ 1/4 0/4 1/4 0/4
Average pathology score 2.3 1.8 1.8 1.3
Disorganization of chondrocytes + 0/4 1/4 3/4 3/4
++ 2/4 3/4 1/4 0/4
+++ 2/4 0/4 0/4 1/4
Average pathology score 2.5 1.8 1.3 1.5
Exposure of subchondral bone + 2/4 1/4 0/4 0/4
++ 1/4 0/4 1/4 0/4
+++ 1/4 0/4 0/4 0/4
Average pathology score 1.8 0.3 0.5 0
Cellular changes of chondrocyte
hypertrophy + 1/4 3/4 1/4 0/4
++ 2/4 1/4 3/4 4/4
+++ 1/4 0/4 0/4 0/4
Average pathology score 2 1.3 1.8 2
Degeneration/necrosis + 0/4 1/4 4/4 2/4
++ 1/4 0/4 0/4 2/4
+++ 3/4 3/4 0/4 0/4
Average pathology score 2.8 2.5 1 1.5
Inﬂammatory cell inﬁltration + 1/4 3/4 2/4 3/4
in synovial tissue ++ 1/4 1/4 1/4 0/4
+++ 2/4 0/4 0/4 1/4
Average pathology score 2.3 1.3 1 1.5
Synovial cell proliferation + 1/4 3/4 3/4 3/4
++ 2/4 0/4 0/4 1/4
+++ 1/4 1/4 1/4 0/4
Average pathology score 2 1.5 1.5 1.3
Safranin-O staining
Reduction of staining in cartilage + 0/4 3/4 1/4 1/4
++ 0/4 0/4 0/4 1/4
+++ 4/4 1/4 0/4 0/4
Average pathology score 3 1.5 0.3 0.8
Total pathology score (average ± S.E.M) 24.5 ±1.31 6 .1 ±1.4a 12.5 ±1.1b 13.4 ±2.2b
+: mild, ++: moderate, and +++: severe.
a,bDenote signiﬁcant diﬀerences (P<0.05, P<0.01) versus the vehicle-treated MIA group. N = 4.Evidence-Based Complementary and Alternative Medicine 7
Table 4: Eﬀect of GCSB-5 on serum TNF-α,I L - 1 β, and IL-10 levels
in MIA-induced osteoarthritic rats.
Group TNF-α
(pg/mL)
IL-1β
(pg/mL)
IL-10
(pg/mL)
Control 30.0 ±4.52 9 .1 ±3.72 7 .8 ±0.6
MIA
Vehicle 85.4 ±6.6b 99.5 ±11.2b 60.4 ±7.2b
GCSB-5
300mg/kg 60.0 ±4.6a,c 102.6 ± 10.4b 91.4 ±8.8b,d
600mg/kg 55.3 ±6.2c 93.9 ± 9.0b 84.5 ±8.5b,c
Diclofenac 5mg/kg 50.1 ±4.0d 49.5 ±7.5d 86.1 ±9.2b,c
The serum concentration of TNF-α,I L - 1 β, and IL-10 was determined using
enzyme-linked immunosorbent assay. The results are presented as mean ±
S.E.M. of 6 rats per group.
a,bDenotesigniﬁcantdiﬀerences (P<0.05,P<0.01)comparedwithcontrol
group.
c,dDenote signiﬁcant diﬀerences (P<0.05, P<0.01) compared with
vehicle-treated MIA group.
IκB-α protein expression decreased 2.0-fold in the vehicle-
treated MIA group, compared to that in the control group
2 days after MIA injection. These changes were signiﬁcantly
inhibited by GCSB-5 treatment (Figure 7).
4. Discussion
Today, cure for OA remains elusive. The management of OA
is largely palliative focusing on the alleviation of symptoms.
Current recommendations for the management of OA
include a combination of nonpharmacological (weight loss,
education programs, and exercise) and pharmacological
interventions (paracetamol, NSAIDs, etc.) [26]. Of the phar-
macological intervention available, analgesics and NSAIDs
have been proven to be highly eﬀective in controlling the
symptoms and signs of OA. However, they have potential
gastrointestinal (GI) adverse eﬀects. Herbal medicinal prod-
ucts (HMPs) are not yet among the recommended treatment
options, although they are used in a variety of oral and top-
ical forms in the treatment of OA. The mechanism of action
of HMPs is broader than that of NSAIDs and/or analgesics
in current use for symptomatic OA. Although the exact
mechanisms of action have not yet been elucidated, there is
no doubt that all herbal medicines act via several pathways,
including inhibition of COX and/or lipoxygenase, inhibition
of cytokine release, inhibition of elastase or hyaluronidase,
and induce antioxidative activity [27]. On the basis of this
knowledge, our experimental herbal extract, GCSB-5, con-
sisted of various herbs known to exhibit antiarthritic, anti-
inﬂammatory and analgesic eﬀects, is expected to show ther-
apeutic activity against OA.
Articular cartilage destruction is a key pathological char-
acteristic of OA. MIA is an inhibitor of glyceraldehyde-3-
phosphate dehydrogenase activity, and therefore an inhibitor
ofglycolysisshowntoinducechondrocytedeathinvitro[28].
Intra-articular injection of MIA induces chondrocyte death
in the articular cartilage of rodent and nonrodent species
[29]. Injection of MIA into the knees of rats provides a
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Figure 3: Activities of MMP-2 (Gelatinase A) and MMP-9 (Gelati-
nase B) assessed by zymography in knee joint cartilages obtained
28 days after MIA injection. The latent and active amounts of
gelatinase were combined to give a total value for each gelatinase.
Each value represents the mean ± S.E.M. from 6 rats per group.
aSigniﬁcantly diﬀerent (P<0.01) from control. bSigniﬁcantly
diﬀerent (P<0.05) from vehicle-treated MIA.
model in which lesions resembling some aspects of human
OA produced quickly and has been suggested as a model
for the study of chondroprotective drugs [30]. In the present
study, we investigated GCSB-5 on the clinical and behavioral
changes associated with MIA-induced OA. Swelling and
limping were apparent as early as 7 days after MIA injection,
after which they became transiently subsided. At 14 days,
there was a second period of knee joint swelling and limping
that was progressively aggravated until day 28. Administra-
tion of GCSB-5 once daily for 28 days signiﬁcantly reduced
the severity of swelling and limping. These results suggest
that GCSB-5 may have potential as a treatment for OA.
Roentgenographic and histological observations strongly
supported the behavioral changes following MIA injection
as well as the protective eﬀect of GCSB-5.
Cartilage comprises an extracellular matrix consisting
of PGs, collagens (types II, IX, XI, and others), and water.
Cartilage PGs consist of a protein core with GAG side chains
[31]. When cartilage is damaged by inﬂammatory mediators
such as rhIL-1α, PGs degrade and consequently release GAG,
which is a typical clinical symptom of OA. GCSB-5 did not
inhibit GAG release at low concentrations, but showed an
inhibitory eﬀect at moderate-to-high concentrations. This
analysis reﬂected the histochemical appearance of cartilage.
SOFG staining showed signiﬁcant PG loss and lesion devel-
opment in subchondral bone which were induced by MIA8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: TNF-α, IL-1β,a n dIL-10 mRNA expressions in cartilage
from knee joints of rats at day 2 after MIA injection. Each value
represents the mean ± S.E.M. from 6 rats per group. a,bSigniﬁcantly
diﬀerent (P<0.01, P<0.05) from control. c,dSigniﬁcantly diﬀerent
(P<0.01, P<0.05) from vehicle-treated MIA.
injection.ThesecartilagedamageswereattenuatedbyGCSB-
5 treatment. Our data suggest that GCSB-5 may protect
articular cartilage from degradation.
MMPs are a family of proteinases that together can de-
grade all extracellular matrix components. Type IV colla-
genases (gelatinases) are members of the MMP family and
are thought to play an important role in the degradation of
extracellular components. The gelatinase subclass can be di-
vided into gelatinase-A (MMP-2) and gelatinase-B (MMP-
9), which is capable of degrading types IV and V collagens,
elastin, and gelatin [32]. MMP-2 is known to be produced by
osteoblasts and tissue structural cells, including ﬁbroblasts
and endothelial cells, whereas MMP-9 is produced by in-
ﬂammatory cells such as macrophages, neutrophils, and eos-
inophils [33, 34]. These MMPs are secreted as latent pre-
cursors and can be activated by limited proteolysis. The in-
creased expression of MMP-2 and -9 in the synovium of
patients with arthritic eﬀusions superiorly reﬂects the
inﬂammatory condition of the joints, and a positive corre-
lation between MMP-9 production and rapid destruction of
thehipjointhasbeendescribedinOA[35].AlthoughGCSB-
5 did not aﬀect MMP-2 and -9 activities 7 days after MIA
injection (data not shown), GCSB-5 especially at a dose of
300mg/kg suppressed MMP-2 and -9 activities 28 days after
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MIA injection. Our results indicate that GCSB-5 inhibits
collagen degradation through inhibition of MMP-2 and -9
activities in late stage of OA.
Matrix turnover is solely dependent on chondrocytes,
which are believed to be the main site of inﬂammatory
mediators production in human OA [36]. Overexpression
of MMPs is induced by several cytokines, such as TNF-
α, IL-1, IL-17, and IL-10. TNF-α and IL-1β drive the
catabolic processes in OA, leading to cartilage degradation.
In this study, the levels of TNF-α, COX-2, and iNOS mRNA
expression were signiﬁcantly increased 2 days after MIA
injection and returned to control level at 28 days (data
not shown). These increases were attenuated by GCSB-5
treatment. On the other hand, a critical function of IL-
10 is to limit inﬂammatory responses [37]. This cytokine
inhibits IL-1β and TNF-α expression and is present in
OA chondrocytes, where it may counteract their catabolic
eﬀects [38]. Interestingly, GCSB-5 treatment signiﬁcantly
potentiated this increase. Our results indicate that GCSB-
5 shows a signiﬁcant anti-inﬂammatory action in the early
stage of OA.
Inappropriate regulation of NF-κBa c t i v i t yh a sb e e n
implicated in the pathogenesis of inﬂammatory diseases,
such as rheumatoid arthritis and OA [39]. NF-κB signal-
ing pathways mediate critical events in the inﬂammatoryEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: COX-2 and iNOS mRNA expressions in cartilage from
kneejointsofratsatday2afterMIAinjection.Eachvaluerepresents
the mean ± S.E.M. from 6 rats per group. aSigniﬁcantly diﬀerent
(P<0.05) from control. bSigniﬁcantly diﬀerent (P<0.05) from
vehicle-treated MIA.
response by chondrocytes, leading to progressive extracellu-
larmatrixdamageandcartilagedestruction.NF-κBmediates
ﬁbronectin fragment-induced chondrocyte activation and
increased expression of proinﬂammatory cytokines, che-
mokinesaswellasMMPssuchasIL-6,IL-8,MCP-1,growth-
related oncogene-α,- β,- γ, and MMP-13 by human articular
chondrocytes [40, 41]. In this study, we showed that GCSB-
5 inhibits nuclear translocation of NF-κB/p65 subunit and
degradation of IκB-α.
Although the results of present study provided clues for
further studies on the pharmacological mechanisms of
GCSB-5, the relationship between the eﬀects and its active
components remains to be clariﬁed. Therefore, the detailed
molecular mechanisms of GCSB-5 and further studies of
anti-inﬂammatory properties of the active ingredients
should be elucidated.
5. Conclusions
These results indicate that GCSB-5 improves OA-induced
cartilage damage, which inhibits MMP activities, down-
regulates the expression of inﬂammatory mediators, and
suppresses NF-κB activity, suggesting that GCSB-5 may be
a potential therapeutic agent for OA.
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